Lymph node metastases. The importance of the microenvironment

Cancer

Volumn 88, Issue 1, 2000, Pages 175-179

  Santin, Alessandro D ^a,b,c  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL INTERACTION; HUMAN; IMMUNE SYSTEM; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHATIC METASTASIS; T-LYMPHOCYTES;

EID: 0033979534     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<175::AID-CNCR24>3.0.CO;2-F     Document Type: Article

References (39)

1. Bailar JC, Gornik HL. Cancer undefeated. N Engl J Med 1997;336:1569-74.
2. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 1976;33:241-59.
3. van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982;79:4718-22.
4. Hollstein M, Moeckel G, Hergenhahn M, Spiegelhalder B, Keil M, Werle-Schneider G, et al. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 1998;405:145-54.
5. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, et al. Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989;58:293-303.
6. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
7. Zinkernagel RM, Pircher H, Ohashi PS, Oehen S, Odermatt B, Mak TW, et al. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev 1991;122:133-71.
8. Chuaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18:493-7.
9. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6.
10. Johnson JG, Jenkins MK. The role of anergy in peripheral T cell unresponsiveness. Life Sci 1994;55:1767-80.
11. Yang G, Mizuno MT, Hellstrom KE, Chen L. B7-negative versus B7-positive tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J Immunol 1997;158:851-8.
12. Mukherji B, Nashed AL, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma: mechanism of induction and specificity of suppression. J Immunol 1986;136:1893-8.
13. Ioannides CG, Whiteside TL. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993;66:91-106.
14. North RJ. Down-regulation of the anti-tumor immune response. Adv Cancer Res 1985;45:1-3.
15. Solowey AC, Rapaport FT. Immunological responses in cancer patients. Surg Gynecol Obstet 1965;14:756-60.
16. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-38.
17. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, et al. Self antigens expressed by solid tumors do not efficiently stimulate naive T cells: implications for immunotherapy. J Exp Med 1997;186:645-53.
18. Melero I, Singhal MC, McGowan P, Haugen HS, Blake J, Hellstrom KE, et al. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus 16. J Virol 1997;71:3998-4004.
19. Abe R, Taneichi N. Lymphatic metastasis in experimental cecal cancer: effectiveness of lymph nodes as barriers to the spread of tumor cells. Arch Surg 1972;104:95-8.
20. Weiss L. The pathophysiology of metastases within the lymphatic system. In: Weiss L, Gilbert HA, Ballon SC. Lymphatic system metastases. Boston: G. K. Hall, 1980:2-40.
21. Cady B. Lymph node metastases: indicators, but not governors, of survival. Arch Surg 1984;119:1067-72.
22. Barker CF, Billingham RF. The role of afferent lymphatics in the rejection of skin homografts. J Exp Med 1968;128:197-221.
23. Rowley DA, Gowans JL, Atkins RC, Ford WL, Smith ME. The specific selection of recirculating lymphocytes by antigen in normal and preimmunized rats. J Exp Med 1972;136:499-513.
24. Sakai K, Chang AE, Shu S. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte responce to a progressive syngeneic murine sarcoma. Cancer Res 1990;50: 4371-6.
25. Matsumara T, Sussman JJ, Krinock RA, Chang AE, Shu S. Characteristics and in vivo homing of long-term T cell lines and clones derived from tumor-draining lymph nodes. Cancer Res 1994;54:2744-50.
26. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
27. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997;57:2943-50.
28. Harada M, Tamada K, Abe K, Onoe Y, Tada H, Takenoyama M, et al. Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state. Int J Cancer 1998;75:400-5.
29. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988; 62:2482-5.
30. Young JW, Inaba K: Dendritic cells as adjuvant for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
31. Kundig TM, Bachmann MF, DiPaolo C, Simard JJL, Battegay M, Lother H, et al. Fibroblasts as efficient antigen presenting cells in lymphoid tissue. Science 1995;268:1343-7.
32. Muller M, Gounari F, Prifti S, Hacker HJ, Schirrmacher V, Khazaie K. Eblac Z tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. Cancer Res 1998;58:5439-46.
33. Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 1994;180:1195-1206.
34. Fisher B. Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer 1977;39:2827-39.
35. Veronesi, U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297:627-30.
36. Sim FH. A prospective randomized study of the efficiency of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978;41:948-56.
37. Fisher B, Redmond C, Fisher ER, and participating NSABP Investigators. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology: an overview of findings. Cancer 1980;46: 1009-25.
38. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antige-pulsed dendritic cells. Nat Med 1996;2: 52-8.
39. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.